Aleš Obr
6PUBLICATIONS
97CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Nov 12, 2022
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.Ales Obr, Katerina Benesova, Andrea Janikova
|Nov 15, 2021
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.Johannes Duell, Aleš Obr, Marinela Augustin
|Oct 15, 2021
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).Livio Pagano, Jon Salmanton-García, Francesco Marchesi
|Aug 31, 2020
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.Ales Obr, Pavel Klener, Tomas Furst
|Aug 06, 2020
Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.Diana Malarikova, Adela Berkova, Ales Obr
|Sep 07, 2018
Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry<sup>†</sup>.Aleš Obr, Vit Prochazka, Tomas Papajik
Pageof 1
Frequent Collaborators
2 joint publications
Pavel Klener
1 joint publications
Michael Svaton
1 joint publications
Eva Kriegova
1 joint publications
Livio Pagano
1 joint publications
Jon Salmanton-García
1 joint publications
Francesco Marchesi
1 joint publications
Alessandro Busca
1 joint publications
Paolo Corradini
1 joint publications
Martin Hoenigl
1 joint publications
Nikolai Klimko
